| Friday,
8 September 2006
08:50
Welcome and introduction
Pieter E. Postmus, MD, PhD and Giorgio V. Scagliotti, MD, PhD
Session
I: State-of-the-art lectures
09:00
The changing epidemiology of lung cancer Carolyn Dresler, MD, MPA
09:20
Sex related differences in lung cancer
Enriqueta Felip, MD
09:40
Diagnostic algorythm
Pieter E. Postmus, MD, PhD
10:00
Staging – toward a new staging system
Pieter E. Postmus, MD, PhD
10:20
Prognostic and predictive factors
Nico van Zandwijk, MD, PhD
10:40
Panel discussion
11:10
Coffee break
Session
II: Rare tumors
11:30
Diagnosis and staging of mesothelioma
Paul Baas, MD, PhD
11:50
Mediastinal tumors
Walter Weder, MD
12:10
Bronchoalveolar carcinoma: Diagnosis and treatment
Giorgio V. Scagliotti, MD, PhD
12:30
The management of malignant pleural mesothelioma
Jan P. van Meerbeeck, MD, PhD
12:50
Discussion
13:10
Lunch break
14:10
Lunch symposium supported by Roche
Session
III: Neuroendocrine tumors of the lung
15:20
Neuroendocrine tumors of the lung: The pathologist’s point
of view
Mauro Papotti, MD
15:40
Bronchoscopic treatment for typical and atypical carcinoids
Tom G. Sutedja, MD
16:00
Treatment concepts in small cell lung cancer
Nicholas Thatcher, MB, BChir, PhD
16:20
Diagnosis and management of large cell neuroendocrine lung carcinoma
Thierry Le Chevalier, MD
16:40
Panel discussion
17:00
Coffee break
Session
IV: Difficult cases in lung cancer I
17:20
A patient with resectable small cell lung cancer
Paul R. De Leyn, MD, PhD
17:50
Supportive care in the lung cancer patient
Peter G. Harper, MD
18:20
Chair summary and take home message
Pieter E. Postmus, MD, PhD and Giorgio V. Scagliotti, MD, PhD
18:30
Adjourn
©
2006 Imedex®, Inc |
Saturday,
9 September 2006
Session
V: Parallel meet the expert sessions
08:00
Diagnosis and treatment of pleural effusion
Nico van Zandwijk, MD, PhD
Biomarkers and
treatment of bone metastases
Paris A. Kosmidis, MD and Peter G. Harper, MD
Lung cancer
in women
Enriqueta Felip, MD and Silvia Novello, MD
Session
VI: Integrated therapeutic approach in lung cancer
09:00
Stage I-II- IIIAN1 NSCLC
Ulrich Gatzemeier, MD
09:20
Treatment of N2 disease
Johan F. Vansteenkiste, MD, PhD
09:40
Therapeutic approaches to stage IIIB patients Paul van Houtte, MD
10:00
A look at the future of lung cancer therapy Rafael Rosell, MD, PhD
10:20
Panel discussion
10:40
Coffee break
Session
VII: Difficult cases in lung cancer II
11:00
The poor performance status patient with NSCLC
Egbert F. Smit, MD, PhD
11:30
Endobronchial treatment
Stefano Gasparini, MD
12:00
Stage IV disease
Wilfried Eberhardt, MD
12:30
Treatment of single site metastases
Ugo Pastorino, MD
13:00
Lunch break
Session
VIII: New agents in lung cancer
Moderator: Christian Manegold, MD
14:30
Toll-Like receptor 9 (TLR 9) - activation for the treatment of advanced
NSCLC Christian Manegold, MD
14:50
Multiple tyrosine kinase inhibitors
Jean-Yves Douillard, MD, PhD
15:10
Vaccines
Giorgio V. Scagliotti, MD, PhD
15:30
EGFR dual inhibitors
Robert Pirker, MD
15:50
Bortezomib
Lucio Crinò, MD
16:10
Apoptotic agents
Giuseppe Giaccone, MD, PhD
16:30
Panel discussion
16:50
Chair summary and take home message
Pieter E. Postmus, MD, PhD and Giorgio V. Scagliotti, MD, PhD
17:00
Adjourn
|
